Menu
Menu
We are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our Multimodal and BioPharma teams for three exciting days of innovation, networking, and insights into AI-powered solutions and breakthroughs to transform precision oncology.
Join us at booth #11 to:
SOPHiA GENETICS is at the 17th Annual Meeting of the Cancer Genomics Consortium. Find us at Booth #29 to see how the SOPHiA DDM™ Platform is helping laboratories move from fragmented workflows to AI-driven, integrated, end-to-end solutions, able to generate actionable, evidence-based insights at scale.
Discover a platform built for the complexity of cancer genomics, across solid tumors and hematologic malignancies, driven by its global community and trusted by 990+ institutions across 75 countries.
Drop by our booth for an in-depth demo of our end-to-end applications:
Booth #29 hours:
Learn more:
Don't miss: 🎤 Science Café Presentation, Lizmery Ferguson Schires | Royal Sonesta Houston Galleria
Whether you're running a high-volume solid tumor program or building out comprehensive hemato-oncology capabilities, our team can show you how SOPHiA DDM™ streamlines the entire process, from concept to implementation.
Book 15 minutes with our team now or simply stop by our booth. See you in Houston.
Most lab leaders arrive at ADLM with the same question: how do we bring NGS in-house, or scale what we already run, without adding headcount, cost, or turnaround time?
At Booth #1172, the AVITI24 system and the SOPHiA DDM™ Platform’s AI-powered analysis run as one connected workflow. Your lab sequences and interprets its own data, and your data stays in-house.
780+ institutions run SOPHiA DDM™ today
70+ countries, standardizing and scaling NGS workflows
Stop by Booth #1172, wherever your lab is.
Tell us where you are, and we’ll tailor the conversation.
Booth #1172 hours:
Tue Jul 28, 9:30 AM–5:00 PM
Wed Jul 29, 9:30 AM–5:00 PM
Thu Jul 30, 9:30 AM–12:00 PM
See how to stand up sequencing and analysis together, without building a bioinformatics team from scratch.
See where SOPHiA DDM™ removes the bottlenecks you already feel: variant interpretation time, workflow standardization, and QC overhead.
Walk through the cost and turnaround math labs are using to build the business case for in-house testing.
Whether you’re evaluating NGS solutions, expanding your test menu, or exploring how AI can strengthen your genomic pipeline, our teams are ready to talk.
Book 15 minutes with our team now, or simply stop by and say hello. See you in Anaheim.
Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21st.
Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.
You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.
Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU
The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.
Reserve your spot today!
El GENOMiCS INSIGHTS Day Panama se llevará a cabo el próximo 30 de julio, en el restaurante Maito. Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica. Durante la jornada abordaremos temas clave como la transformación del diagnóstico genómico en Latinoamérica, las nuevas posibilidades clínicas de la biopsia líquida y experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™. Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región. A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Restaurante Maito
Date: 30 de julio
Time: 18h00-21h:00
18:00 – 18:30
Transformando el diagnóstico genómico en Latinoamérica con SOPHiA GENETICS.
Gabriela Acosta, Sales Executive LATAM, SOPHiA GENETICS
18:30 – 19:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
19:00 - 19:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
19:30 – 21:00
Dinner & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform.
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
We are thrilled to be back at 16th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
European Society for Medical Oncology (ESMO) Annual Meeting
SOPHiA GENETICS is excited to be part of the European Society For Medical Oncology (ESMO) Annual Meeting.
You will have the chance to chat with our experts at booth #8068 to discuss our solutions for BioPharma and to demo the universal SOPHiA DDM™ Platform.
Visit us at the Booth and find out how to:
✅ Transform your precision therapy journey with next-generation genomics solutions tailored to your unique requirements
✅ Optimize each stage of drug development with efficient end-to-end Clinical Trial Assay (CTA) and CDx development
✅ Rise above the noise and trust your results with decentralized and best-in-class NGS solutions
✅ Transform oncology data complexity into valuable insights with the power of AI
✅ Streamline your market access strategy by unveiling insights from real-world data
✅ Accelerate global testing adoption and enable sustainable patient access to precision therapies by harnessing the vast global SOPHiA DDM® network
Meet us there!
The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.
We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.
Key Discussion Points:
Learning Objectives:
July 1, 2026 | 1:00PM SGT
Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. The new MSK-IMPACT® Flex powered with SOPHiA DDM™ solution offers an agile and modular approach to CGP, enabling labs to achieve flexible, cost-efficient, and scalable analysis of solid tumors.
Built on the expert-designed MSK-IMPACT® assay and combined with the adaptive analytics of the SOPHiA DDM™ Platform, this end-to-end solution delivers high-resolution profiling of complex biomarkers from DNA and RNA. Labs can tailor biomarker coverage to each sample, with the flexibility to add RNA and homologous recombination deficiency (HRD) analysis as needed.
By attending this session, you will:
Presenters:
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
July 15, 2026 | 1:00 PM SGT
Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers. In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay.
Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.
In this session you will:
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.